Zacks Investment Research on MSN
Does KalVista Pharmaceuticals (KALV) have the potential to rally 117.98% as Wall Street analysts expect?
KalVista Pharmaceuticals, Inc. (KALV) closed the last trading session at $15.24, gaining 2.6% over the past four weeks, but ...
KalVista Pharmaceuticals Inc (NASDAQ:KALV) announced a loss of -$20.09M in its most recent earnings update. Although some investors expected this, their belief in the path to profitability for KALV ...
Shares of KalVista Pharmaceuticals KALV have soared 36% in the past week, all thanks to the FDA’s approval of its lead pipeline drug for the hereditary angioedema (HAE) indication. Earlier this week, ...
Short interest in KalVista Pharmaceuticals Inc (NASDAQ:KALV) decreased during the last reporting period, falling from 10.06M to 10.04M. This put 22.45% of the company's publicly available shares short ...
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Okta Inc (Symbol: OKTA), where a total of 142,673 contracts have traded so far, ...
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
KalVista Pharmaceuticals Inc. (NASDAQ: KALV) on Thursday reported early commercial momentum for its hereditary angioedema treatment EKTERLY, highlighting growing prescriber adoption, repeat ...
KalVista Pharmaceuticals develops oral small-molecule therapies for hereditary angioedema targeting plasma kallikrein and Factor XIIa. Sebetralstat completed Phase 3 trials and submitted an NDA in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results